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Abstract
Introduction: Platelet-derived growth factor BB (PDGF-BB) plays an important role in the development of GD (Graves’ disease). However, 
it is still unknown whether PDGF-BB is expressed in peripheral blood and whether the expression of PDGF-BB contributes to GD. We aim 
to study the expression of PDGF-BB, hypoxia inducible factor (HIF)-1a and C-C motif chemokine receptor (CCR)-2 in peripheral blood 
of patients with GD and explore its effect and potential mechanism in pathogenesis. 
Material and methods: 41 patients with GD (GD group) and forty-five healthy people (control group) were chosen. The concentration of 
PDGF-BB and HIF-1a in peripheral blood specimens were detected and compared between the two groups. The expression of CCR2 in 
macrophages in the peripheral blood specimens were examined using FCM (Flow Cytometry). 
Results: Both PDGF-BB and HIF-1a were expressed in human peripheral blood from the two groups. Compared with specimens from 
healthy people, there were statistically increased concentrations of PDGF-BB and HIF-1a in the GD group (P < 0.05). The proportion 
of CCR2-positive macrophages in peripheral blood in the GD group was significantly higher than that in the control group (P < 0.05). 
Conclusions: CCR2-positive macrophages may induce the expression of PDGF-BB through HIF-1a signal, and the high expression of 
PDGF-BB may be involved in the pathogenesis of GD. (Endokrynol Pol 2018; 69 (1): 9–15)
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Streszczenie
Wprowadzenie: Czynnik wzrostu pochodzenia płytkowego BB (platelet-derived growth factor BB, PDGF-BB) odgrywa ważną rolę w roz-
woju choroby Gravesa-Basedowa (Graves’ disease, GD). Jednak wciąż nie wiadomo, czy PDGF-BB ulega ekspresji we krwi obwodowej 
i czy ekspresja PDGF-BB przyczynia się do GD. Badanie przeprowadzono w celu zbadania ekspresji PDGF-BB, czynnika indukowanego 
hipoksją-1a (hypoxia inducible factor-1a, HIF-1a) i receptora chemokiny C-C typu 2 (C-C motif chemokine receptor-2, CCR-2) we krwi obwo-
dowej pacjentów z GD i zbadania wpływu tych cząsteczek i potencjalnego mechanizmu ich działania w patogenezie choroby.
Materiał i metody: Do badania włączono 41 pacjentów z GD (grupa GD) i 45 osób zdrowych (grupa kontrolna). Stężenie PDGF-BB i HIF-
-1a w próbkach krwi obwodowej oznaczono i porównano między grupami. Do pomiaru ekspresji CCR2 w makrofagach krwi obwodowej 
zastosowano metodę cytometrii przepływowej (flow cytometry, FCM).
Wyniki: W obu grupach badanych stwierdzono ekspresję PDGF-BB i HIF-1a we krwi obwodowej. W grupie GD odnotowano istotne 
statystycznie wyższe stężenia PDGF-BB i HIF-1a niż u osób zdrowych (p < 0,05). Odsetek makrofagów CCR2-dodatnich we krwi obwo-
dowej w grupie GD był istotnie wyższy niż w grupie kontrolnej (p < 0,05).
Wnioski: Makrofagi CCR2-dodatnie mogą indukować ekspresję PDGF-BB za pośrednictwem sygnału HIF-1a, a wysoka ekspresja PDGF-
-BB może odgrywać rolę w patogenezie GD. (Endokrynol Pol 2018; 69 (1): 9–15)
Słowa kluczowe: PDGF-BB, Choroba Gravesa i Basedowa, HIF-1a, makrofagi, immunologia
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Introduction
GD is an autoimmune disease, and the current research 
on it mainly focuses on its immunological pathogenesis. 
PDGF belong to the family of vascular endothelial 
growth factor (VEGF), and is mostly present as dimer 
[1, 2]. PDGF-BB, one member of the PDGF family [3, 4], 
has the ability to promote fibrosis, muscle growth and 
angiogenesis [5, 6].
HIF-1a is a transcription factor involved in homeo-
stasis of oxygen concentration. Inflammatory cytokines 
play an important role in the regulation of HIF-1 alpha 
protein accumulation, DNA binding activity and the ex-
pression of downstream factors [7]. CCR2 is the main re-
ceptor of monocyte chemoattractant protein-1 (MCP-1), 
which is a member of the chemokine CC subfamily [8]. 
In chemotaxis, MCP-1 and CCR2 combine to activate 
intracellular signalling pathways and induce cell migra-
tion [9]. Some scholars believe that MCP-1 can regulate 
HIF-1a gene expression, and MCP-1 mainly exerts its 
biological effects by binding to the chemokine receptor 
CCR2 [10].
Several studies have shown that overexpression of 
PDGF-BB is closely related to cancer, atherosclerosis and 
fibrotic diseases [11, 12]. PDGF-BB may also be involved 
in the pathogenesis of GD by promoting fibrosis, oede-
ma, inflammation, and non-specific immune response 
[13]. However, there have been few reports about the 
research on the expression of PDGF-BB in peripheral 
blood. In this study, we examined the expression of 
PDGF-BB, HIF-1a, and CCR2 in peripheral blood and 
analysed the correlation between PDGF-BB and GD. 
Materials and methods
Subjects
A total of 41 patients (male: 24; female: 17; average age: 
34 ± 12.6 years) with GD were initially diagnosed by 
ultrasound and confirmed in the Department of En-
docrinology from October 2013 to June 2016. Healthy 
controls (n = 41; male: 14; female: 27; average age: 36 
± 10.3 years) from the medical examination centre of 
our hospital were included in this study. Inclusion cri-
teria for GD [14] were: typical fatigue, heat intolerance, 
sweating, irritability, palpitations, tremor, hypermeta-
bolic syndrome, goitre, exophthalmos and increased 
serum level of FT3 and FT4 and decreased level of TSH.
Main reagents and instruments
Calf serum and phosphate buffer solution were pur-
chased from GIBCO (New York, USA). PDGF-BB and 
HIF-1a ELISA assay kits were purchased from R & D 
(Minnesota, USA). PE-labelled rabbit anti-human CCR2, 
FITC-labelled rabbit anti-human CD68 antibody and 
isotype control antibody IgG were purchased from BD 
Biosciences (New York, USA). Haemolytic agents were 
purchased from Invitrogen (California, USA). Instru-
ments used in this study included Mylab90 ultrasonic 
device (Esaote, Shenzhen, China), a Beckman FC500 
flow cytometer (Beckman, California, USA) and a mi-
croplate reader (New York, USA).
Ultrasound diagnosis of GD
Longitudinal and transverse sections of thyroids were 
examined by Mylab90 ultrasonic device using high-
frequency linear array probe (8–13 MHz). Thyroid size, 
shape, echo characteristics, blood flow, and peripheral 
tissues were examined. Left and right lobe diameter, 
vertical diameter, thickness of the isthmus, thyroid 
artery peak systolic velocity (PSV), and the resistance 
index (RI) were measured at the standard sections.
Peripheral blood sample preparation
Peripheral blood (2 mL) from the subjects was collected 
into anticoagulant tubes. Plasma samples were obtained 
after centrifugation at 1800 rpm, 4°C for 5 min. The re-
maining red blood cells in the anticoagulant tube were 
lysed by adding 1 mL of distilled water. After centrifuga-
tion at 1800 rpm at room temperature for 5 min, the cell 
pellet containing mononuclear cells was harvested and 
used for subsequent flow cytometry analysis.
Detection of PDGF-BB and HIF-1a expression in 
peripheral blood by ELISA
PDGF-BB and HIF-1a plasma levels were determined 
by ELISA as described by the manufacturer (R&D). 
The concentration was determined by an ELISA reader 
at 450 nm. The percentage of PDGF-BB and HIF-1a 
results falling below the limit of sensitivity was stated 
for each study subgroup and calculations were based 
on observations above the detection limits. All ELISA 
readings of PDGF-BB and HIF-1a measurements were 
within the respective detection limits.
Flow cytometry detection of CCR2 positive mac-
rophages in peripheral blood 
The mononuclear cells were adjusted to the concentra-
tion of 2×105 /mL and each reaction contained 5×104 
cells. The resultant cells were stained with FITC-con-
jugated rabbit anti-human CD68 and PE-conjugated 
rabbit anti-human CCR2. Together with the samples 
stained with non-immunised rabbit IgG mAb as an 
isotype control. 
Statistical analysis
The means and standard error of the mean (SEM) were 
calculated for all parameters determined in the study. 
Data were analysed statistically using one-way analysis 
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of variance (ANOVA), two-tailed Student’s t test, or chi 
square test. A value of P < 0.05 was considered statisti-
cally significant.
Results
General information of the subjects
All of the 41 subjects with GD had high metabolic 
syndrome, e.g. tachycardia, palpitations, bulimia, and 
significantly enlarged thyroid. There were 37 patients 
with exophthalmos (The exophthalmos was 17.27 ± 
1.12 mm), and 1 case with infiltrative exophthalmos 
(The exophthalmos was 25 mm). The exophthalmus 
of infiltrative exophthalmos is 16–18 mm, and the 
exophthalmos of infiltrative exophthalmos is 19 mm 
[15]. Serum free T3, T4 concentration in the GD group 
was higher than in normal subjects; the concentra-
tions were 21.65 ± 7.13 pmol/L (FT3) and 63.46 ± 
25.71 pmol/L (FT4), respectively. The maximum value 
was 30.80 pmol/L (FT3) and 120.20 pmol/L (FT4). 
Thirty-nine patients’ TSAbs were positive, and the 
TSAb positive rate in the Graves’ disease group was 
95% (Table I).
Ultrasound examination 
Dimensional ultrasound showed that thyroid volume 
was significantly increased in patients with GD (where 
the isthmus had no significant thickening). The thyroid 
was encapsulated, with clear boundaries, and enhanced 
and evenly distributed echoes. Colour Doppler showed 
that the blood supply of the thyroid is abundant, signifi-
cantly increased thyroid blood flow with flashing bright 
spot representative of a “sea of fire” sign (Figure 1A). 
Thyroid arteries were expanded and Doppler can detect 
the high-speed, low resistance turbulence spectrum 
(Figure 1B).
Table I. The clinical conditions of the two groups
Tabela I. Dane kliniczne obu grup pacjentów
Characteristics Control group GD group P
Clinical manifestation
Participants [n] 41 41
Age [y] 36 ± 10.3 34 ± 12.6 0.25
Infiltrative exophthalmos [n] 0 1
High metabolic syndrome [n] 0 41 < 0.01
FT3 [pmol/L] Normal 21.65 ± 7.13 < 0.01
FT4 [pmol/L] Normal 63.46 ± 25.71 < 0.01
TSAb positive rate [%] 0 95 (39/41) < 0.01
Data presented as n or mean ± SD. 
P-value: t-testing (age); chi-square-testing (high metabolic syndrome)
Figure 1. The CDFI and PW-DTI of GD
Rycina 1. CDFI i PW-DTI choroby Gravesa-Basedowa
A B
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Expression of PDGF-BB and HIF-1a in the pe-
ripheral blood
The concentration of PDGF-BB and HIF-1a in the se-
rum of patients with GD was 189.16 ± 22.37 pg/mL and 
239.69 ± 32.97 pg/mL, respectively. The concentration of 
PDGF-BB and HIF-1a in the serum of control subjects 
was 121.12 ± 29.38 pg/mL and 106.45 ± 44.39 pg/mL, 
respectively. The concentration PDGF-BB and HIF-1a in 
the serum of patients with GD was significantly higher 
than that in the control subjects (P < 0.05) (Figure 2A 
and 2B). The concentration of PDGF-BB and HIF-1a in 
the seven patients with higher T3 concentration was 
241.35 ± 51.22 pg/mL and 287.32 ± 37.46 pg/mL, respec-
tively, which was significantly higher than the average 
concentration of PDGF-BB and HIF-1a in patients with 
GD (P < 0.05) (Figure 2C and 2D).
Expression of CCR2 positive macrophage
Flow cytometry showed that the positive rate of CD68 
on the peripheral mononuclear cells was 13.19 ± 4.55% 
and these cells were macrophages. Subsequently, CCR2 
expression on macrophage was measured. CCR2 was 
expressed on 55.25 ± 10.44% of macrophages in the 
GD group (Figure 3B), while in the control subjects, 
CCR2-positive rate was 41.21 ± 11.26% (Figure 3A). 
The CCR2-positive rate in GD group was significantly 
higher than that in the normal group (P < 0.05) (Figure 
3D). Furthermore, The CCR2-positive rate in the seven 
patients with higher T3 concentration was 62.16 ± 
9.85%, which was significantly higher than the average 
CCR2-positive rate in the patients with GD (P < 0.05) 
(Figure 3E).
Correlation between PDGF-BB and CCR2 posi-
tive macrophages
Statistical analysis showed that PDGF-BB concentra-
tion in the peripheral blood was positively correlated 
with the CCR2-positive rate on macrophage (R^2 = 
0.5777) (Figure 4).
Discussion
GD is a kind of refractory disease [16]. The main mani-
festation of GD is hyperthyroidism. Hyperthyroidism 
can exacerbate immune disorders, which leads to 
increased anti-TR (anti-thyroid hormone receptors) 
antibody production, and thus increases thyrotoxicosis 
and creates a vicious cycle [17]. Foreign studies have 
found that PDGF-BB is involved in the pathogenesis of 
GD [1]. According to the data analysis, PDGF-BB can be 
regarded as an important regulatory factor in the patho-
physiology of GD, especially Graves ophthalmopathy. 
Figure 2. The concentration of PDGF-BB and HIF-1a in peripheral blood. “*”means that the difference between the two groups 
was statistically significant (P < 0.05)
Rycina 2. Stężenie PDGF-BB i HIF-1a w krwi obwodowej. „*”różnica znamienna statystycznie pomiędzy dwoma grupami 
(P < 0,05)
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Figure 3. The expression of CCR2 in peripheral blood of macrophages. Figure A represents the control group; Figure B represents 
GD; Figure C represents serious GD; “*” means that the difference between the two groups was statistically significant (P 
< 0.05). FL1 Log refers to fluorescein isothiocyanate (FITC) axis and FL2 Log refers to P-phycoerythrin (PE) axis. The cells 
in the gate were positive macrophages
Rycina 3. Ekspresja CCR2 w makrofagach krwi obwodowej. Rycina A przedstawia grupę kontrolną; Rycina B grupę pacjentów 
z GD; Rycina C przedstawia grupę pacjentów z chorobą GD w fazie zaawansowanej; „*”różnica znamienna statystycznie 
pomiędzy grupami (P < 0.05). FL1 Log — izotiocyjanian fluoresceiny (FITC), FL2 Log — fikoerytryna. Odnotowano 
makrofagi dodatnie
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However, the expression of PDGF-BB in the peripheral 
blood of patients and its specific mechanisms need to 
be further studied.
Therefore, we detected the expression of PDGF-BB, 
HIF-1a, and CCR2 in the peripheral blood of patients. 
Compared with the control group, the expression of 
PDGF-BB, HIF-1a and CCR2 in peripheral blood of pa-
tients with GD increased significantly. Furthermore, the 
expression of PDGF-BB, HIF-1a and CCR2 in periph-
eral blood of patients with severe disease progression 
was higher than that in patients with mild symptoms. 
These results showed that the expression of PDGF-BB 
in peripheral blood may be related to the occurrence 
and development of GD.
This study demonstrated that the expression of 
PDGF-BB in peripheral blood of GD had an increasing 
trend, which may be caused by the increased HIF-1a. 
HIF-1a can cause CCR2-positive macrophage prolifera-
tion activity and then promote the secretion of VEGF 
and PDGF-BB. Currently, molecularly targeted therapy 
is an important means of clinical control of disease 
development. We may take PDGF-BB as a target and 
achieve effective control of Graves by blocking its mo-
lecular signalling pathway. The abnormal expression 
of PDGF-BB in peripheral blood of Graves patients 
provides a valuable experimental basis for clinical ap-
plication.
The changes of PDGF-BB expression may be re-
lated to the immune regulation disorder of GD, and 
the heterogeneity of macrophages. We found that the 
expression of CCR2-positive macrophages in periph-
eral blood of patients with GD increased significantly, 
and the expression in patients with severe disease was 
also higher than that of patients with mild disease. 
The results indicate that the number of CCR2-positive 
macrophages in patients with GD was disordered. 
Macrophages are the major secretory cells of PDGF-BB. 
Furthermore, the correlation between PDGF-BB and 
positive macrophage CCR2 expression was analysed 
and the results showed that they were positively corre-
lated. Thus, the expression of PDGF-BB may be related 
to the imbalance of CCR2-positive macrophages.
We also examined the expression of HIF-1a in 
peripheral blood and the results showed that HIF-1a 
expression had the similar trends with PDGF-BB ex-
pression. Previous studies have shown that HIF-1a is 
an important factor to stimulate macrophages [18, 19]. 
Upon HIF-1a stimulation, macrophages can upregulate 
the expression of VEGF and PDGF-BB, thus participat-
ing in the pathological process of GD.
Conclusions
Our present study investigated the expression of PDGF-
BB in peripheral blood of patients with GD as well as 
the potential regulatory mechanisms, which laid the 
foundation for further exploration of the role of PDGF-
BB in the pathological process of GD.
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